Literature DB >> 33037580

Primary hyperparathyroidism in pregnancy: observations from the Indian PHPT registry.

R Pal1, S K Bhadada2, N Gupta1, A Behera3, N Aggarwal4, A Aggarwal1, K V Raviteja1, U N Saikia5, G Kaur1, S M Arvindbhai1, R Walia1.   

Abstract

PURPOSE: To present the data on primary hyperparathyroidism (PHPT) in pregnancy from India obtained from a large database maintained over 15 years.
METHODS: We retrieved data of all women with gestational PHPT from the Indian PHPT registry between July 2005 and January 2020, and compared their clinical, biochemical, and other characteristics with age-matched non-pregnant women with PHPT.
RESULTS: Out of 386 women, eight had gestational PHPT (2.1%). The common presenting manifestations were acute pancreatitis (50%) and renal stone disease (50%); two were asymptomatic. Five women (62.5%) had a history of prior miscarriages. Seven patients (88%) had preeclampsia during the present gestation. Serum calcium and intact parathyroid hormone (iPTH) were not statistically different from the age-matched non-pregnant PHPT group. Six patients with mild-to-moderate hypercalcemia were medically managed with hydration with/without cinacalcet while one patient underwent percutaneous ethanol ablation of the parathyroid adenoma; none underwent surgery during pregnancy. Mean serum calcium maintained from treatment initiation till delivery was 10.5 ± 0.4 mg/dl. One patient had spontaneous preterm delivery at 36 weeks; the remaining patients had normal vaginal delivery at term. None had severe preeclampsia/eclampsia. Fetal outcomes included low birth weight in three newborns (37.5%); two of them had hypocalcemic seizures.
CONCLUSION: The prevalence of gestational PHPT was 2.1% in this largest Indian PHPT cohort, which is higher than that reported from the West (< 1%). Gestational PHPT can lead to preeclampsia and miscarriage. Pregnant PHPT patients with mild-to-moderate hypercalcemia can be managed with hydration/cinacalcet; however, long-term safety data and large-scale randomized controlled trials are required.

Entities:  

Keywords:  Cinacalcet; Gestational PHPT; India; PHPT in pregnancy; Primary hyperparathyroidism

Mesh:

Year:  2020        PMID: 33037580     DOI: 10.1007/s40618-020-01441-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

Review 1.  Primary hyperparathyroidism in pregnancy: a case series and literature review.

Authors:  Naile Gokkaya; Adem Gungor; Arzu Bilen; Habib Bilen; Darina Gviniashvili; Yusuf Karadeniz
Journal:  Gynecol Endocrinol       Date:  2016-05-31       Impact factor: 2.260

2.  Hyperparathyroidism complicating pregnancy: a diagnostic challenge?

Authors:  S N Jibhkate; A G Valand; S Ansari; B M Bharambe
Journal:  J Postgrad Med       Date:  2014 Jul-Sep       Impact factor: 1.476

Review 3.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

4.  Hyperparathyroidism in pregnancy: options for localization and surgical therapy.

Authors:  Todd P W McMullen; Diana L Learoyd; David C Williams; Mark S Sywak; Stan B Sidhu; Leigh W Delbridge
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

5.  Pregnancy outcomes in women with primary hyperparathyroidism.

Authors:  Dania Hirsch; Vered Kopel; Varda Nadler; Sigal Levy; Yoel Toledano; Gloria Tsvetov
Journal:  J Clin Endocrinol Metab       Date:  2015-03-09       Impact factor: 5.958

6.  Primary hyperparathyroidism: insights from the Indian PHPT registry.

Authors:  Sanjay Kumar Bhadada; Ashutosh Kumar Arya; Satinath Mukhopadhyay; Rajesh Khadgawat; Suja Sukumar; Sailesh Lodha; Deependra N Singh; Anjali Sathya; Priyanka Singh; Anil Bhansali
Journal:  J Bone Miner Metab       Date:  2017-03-31       Impact factor: 2.626

Review 7.  Primary hyperparathyroidism in pregnancy: evidence-based management.

Authors:  Peter F Schnatz; Stephen L Curry
Journal:  Obstet Gynecol Surv       Date:  2002-06       Impact factor: 2.347

8.  Pregnancy outcomes in women with primary hyperparathyroidism.

Authors:  Ali Abood; Peter Vestergaard
Journal:  Eur J Endocrinol       Date:  2014-04-17       Impact factor: 6.664

9.  Seventeen Cases of Primary Hyperparathyroidism in Pregnancy: A Call for Management Guidelines.

Authors:  Aimee Natasha DiMarco; Karim Meeran; Ioannis Christakis; Vinpreet Sodhi; Catherine Nelson-Piercy; Neil Samuel Tolley; Francesco Fausto Palazzo
Journal:  J Endocr Soc       Date:  2019-02-20

10.  Micronucleus Assay: An Early Diagnostic Tool to Assess Genotoxic Changes in Patients with Tobacco Use, Oral Leukoplakia and Oral Submucous Fibrosis.

Authors:  Moulshree Kohli; Puneet Ahuja; Monica Mehendiratta; Mohit Sharma; Jahnobi Dutta
Journal:  J Clin Diagn Res       Date:  2017-09-01
View more
  3 in total

Review 1.  Addressing male sexual and reproductive health in the wake of COVID-19 outbreak.

Authors:  A Sansone; D Mollaioli; G Ciocca; E Limoncin; E Colonnello; W Vena; E A Jannini
Journal:  J Endocrinol Invest       Date:  2020-07-13       Impact factor: 4.256

2.  Hypercalcemia during pregnancy: management and outcomes for mother and child.

Authors:  Natasha M Appelman-Dijkstra; Diana- Alexandra Ertl; M C Zillikens; Lars Rjenmark; Elizabeth M Winter
Journal:  Endocrine       Date:  2021-02-05       Impact factor: 3.633

3.  European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders.

Authors:  Jens Bollerslev; Lars Rejnmark; Alexandra Zahn; Ansgar Heck; N M Appelman-Dijkstra; Luis Cardoso; Fadil M Hannan; Filomena Cetani; Tanja Sikjær; Anna Maria Formenti; Sigridur Björnsdottir; Camilla Schalin-Jantti; Zhanna Belaya; Fraser Wilson Gibb; Bruno Lapauw; Karin Amrein; Corinna Wicke; Corinna Grasemann; Michael Krebs; Eeva M Ryhänen; Ozer Makay; Salvatore Minisola; Sebastien Gaujoux; Jean-Philippe Bertocchio; Zaki K Hassan-Smith; Agnès Linglart; Elizabeth M Winter; Martina Kollmann; Hans-Georg Zmierczak; Elena Tsourdi; Stefan Pilz; Heide Siggelkow; Neil J Gittoes; Claudio Marcocci; Peter Kamenicky
Journal:  Eur J Endocrinol       Date:  2022-01-13       Impact factor: 6.664

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.